Evidence map›Paper›PMID 39699836›Full record

ArticleInfection2025

Risk factors and outcome of Pseudomonas aeruginosa bloodstream infections (PABSI) in hematological patients: a single center retrospective cohort study.

Johanna Kessel, Gesine Bug, Björn Steffen, Uta Brunnberg, Maria J G T Vehreschild, Sarah Weber, Sebastian Scheich, Fabian Lang, Hubert Serve, Eva Herrmann and 1 more

Abstract read
In one paragraph

Article in Infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Observational
  3. Article
  4. Predictors of Mortality inPathogens (Basel, Switzerland) · 2026
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Johanna KesselDepartment of Internal Medicine 2, Infectious Diseases, Goethe University Frankfurt, University Hospital Frankfurt, Theodor Stern-Kai 7, 60590, Frankfurt, Germany. Johanna.Kessel@unimedizin-ffm.de.
Gesine BugDepartment of Medicine 2, Hematology/Oncology, Goethe University Frankfurt, University Hospital Frankfurt, Theodor Stern-Kai 7, 60590, Frankfurt, Germany.
Björn SteffenDepartment of Medicine 2, Hematology/Oncology, Goethe University Frankfurt, University Hospital Frankfurt, Theodor Stern-Kai 7, 60590, Frankfurt, Germany.
Uta BrunnbergDepartment of Medicine 2, Hematology/Oncology, Goethe University Frankfurt, University Hospital Frankfurt, Theodor Stern-Kai 7, 60590, Frankfurt, Germany.
Maria J G T VehreschildDepartment of Internal Medicine 2, Infectious Diseases, Goethe University Frankfurt, University Hospital Frankfurt, Theodor Stern-Kai 7, 60590, Frankfurt, Germany.
Sarah WeberDepartment of Medicine 2, Hematology/Oncology, Goethe University Frankfurt, University Hospital Frankfurt, Theodor Stern-Kai 7, 60590, Frankfurt, Germany.
Sebastian ScheichDepartment of Medicine 2, Hematology/Oncology, Goethe University Frankfurt, University Hospital Frankfurt, Theodor Stern-Kai 7, 60590, Frankfurt, Germany.
Fabian LangDepartment of Medicine 2, Hematology/Oncology, Goethe University Frankfurt, University Hospital Frankfurt, Theodor Stern-Kai 7, 60590, Frankfurt, Germany.
Hubert ServeDepartment of Medicine 2, Hematology/Oncology, Goethe University Frankfurt, University Hospital Frankfurt, Theodor Stern-Kai 7, 60590, Frankfurt, Germany.
Eva HerrmannInstitute of Biostatistics and Mathematical Modelling, Goethe University Frankfurt, Frankfurt, Germany.
Michael HogardtInstitute of Medical Microbiology and Infection Control, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBloodstream infections caused by Pseudomonas aeruginosa (PABSI) in hematological patients are associated with high morbidity and mortality. We investigated the epidemiology, risk factors, and outcomes of PABSI at our center.

methodsAll adult hematological patients with PABSI between January 2013 and July 2023 were included. Demographic and clinical characteristics, antimicrobial susceptibilities, antibiotic therapy, fluoroquinolone-prophylaxis, source of infection, and 30-day outcome were recorded. Descriptive statistics, tests for difference, and logistic regression models were performed.

resultsFifty patients with PABSI were identified with a median age of 58.5 years (range 24-78). 37 patients (74%) had severe neutropenia, 20 (40%) received allogeneic HSCT, and 29 (58%) had acute leukemia. A total of 34 (68%) had received timely appropriate anti-pseudomonal antibiotic therapy. The most common presumed cause of PABSI was mucositis (n = 16, 32%), followed by pneumonia (8, 16%) and skin and soft tissue infections (n = 6, 12%). Empirical combination therapy was used in 16 (32%) patients, while targeted combination therapies were used in 27 (54%) patients. P. aeruginosa detection led to treatment change in 31 (62%) cases. The overall 30-day survival rate was 78% (n = 39). Carbapenem-resistance occurred in 34% (n = 17), and multidrug-resistance (MDR) in 20% (n = 10). Prior antibiotic exposure was associated with resistance. Appropriate antibiotic therapy was associated with survival, whereas antibiotic resistance and organ infection were associated with a fatal outcome.

conclusionPrior antibiotic exposure in hematological patients is associated with resistance in PABSI, which is a major risk factor for a fatal outcome. Antibiotic stewardship efforts should be intensified and fluoroquinolone prophylaxis needs to be reconsidered.

Indexed as

BacteremiaPseudomonas aeruginosaPseudomonas InfectionsAdultAgedAnti-Bacterial AgentsFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsTreatment OutcomeYoung AdultAnti-Bacterial AgentsAntibiotic resistanceAntimicrobial stewardshipBloodstream infectionsFluoroquinoloneprophylaxisHematological patientsPseudomonas aeruginosa

Identifiers

PMID39699836
PMCPMC12316746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.